高级搜索

国际肺癌研究协会第八版国际肺癌TNM分期修订稿解读

张用, 毕建平, 皮国良, 曾凡玉, 韩光, 胡德胜

张用, 毕建平, 皮国良, 曾凡玉, 韩光, 胡德胜. 国际肺癌研究协会第八版国际肺癌TNM分期修订稿解读[J]. 肿瘤防治研究, 2016, 43(4): 313-318. DOI: 10.3971/j.issn.1000-8578.2016.04.016
引用本文: 张用, 毕建平, 皮国良, 曾凡玉, 韩光, 胡德胜. 国际肺癌研究协会第八版国际肺癌TNM分期修订稿解读[J]. 肿瘤防治研究, 2016, 43(4): 313-318. DOI: 10.3971/j.issn.1000-8578.2016.04.016
ZHANG Yong, BI Jianping, PI Guoliang, ZENG Fanyu, HAN Guang, HU Desheng. An Interpretation of Revised Version of International Association for Study of Lung Cancer for Forthcoming 8th Edition of TNM Classification for Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2016, 43(4): 313-318. DOI: 10.3971/j.issn.1000-8578.2016.04.016
Citation: ZHANG Yong, BI Jianping, PI Guoliang, ZENG Fanyu, HAN Guang, HU Desheng. An Interpretation of Revised Version of International Association for Study of Lung Cancer for Forthcoming 8th Edition of TNM Classification for Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2016, 43(4): 313-318. DOI: 10.3971/j.issn.1000-8578.2016.04.016

国际肺癌研究协会第八版国际肺癌TNM分期修订稿解读

详细信息
    作者简介:

    张用(1985-),男,博士,医师,主要从事以头颈和胸部恶性肿瘤为主的肿瘤放化疗等综合治疗的研究

    通讯作者:

    韩光,E-mail: hg7913@163.com

    胡德胜,E-mail: hds_005@163.com

  • 中图分类号: R734.2

An Interpretation of Revised Version of International Association for Study of Lung Cancer for Forthcoming 8th Edition of TNM Classification for Lung Cancer

  • 摘要: 肺癌导致的死亡人数位于各类恶性肿瘤之首,它是对人类健康和生命威胁最大的恶性肿瘤之一。肺癌的TNM分期系统描述了肺癌的生长和扩散等信息,对于指导其临床治疗起了非常重要的作用。目前临床上广泛采用的是国际抗癌联盟(Union for International Cancer Control, UICC)和美国癌症联合会(American Joint Committee on Cancer, AJCC)于2009年发布的第七版肺癌TNM分期。随着肺癌综合治疗的发展以及临床实践模式的改变,肺癌的疗效及其预后也有了明显的改变,旧的分期标准可能难以满足目前的临床需求。因此,国际肺癌研究协会(international association for the study of lung cancer, IASLC)于2014年就开始进行最新一轮的肺癌TNM分期标准修订研究计划。本次分期研究克服了以往分析数据均为回顾性数据的缺陷,采用囊括了回顾性和前瞻性数据的新数据库。该数据库主要是由1999—2010年间新确诊的94 708名肺癌患者数据组成。通过对该数据库分析研究,国际肺癌研究协会对TNM分期进行了相应的修改,并最终在2015年发表了第八版国际肺癌TNM分期的修订稿。本文就该修订稿的细节进行解读。

     

    Abstract: Lung cancer is the leading cause of deaths from all cancers worldwide. TNM staging system can describe the information of the growth and spread of lung cancer, and it also plays a very important role in guiding the clinical treatment. The 7th edition of the TNM staging of lung cancer being widely used in worldwide was published by the Union for International Cancer Control (UICC) and American Joint Committee on Cancer (AJCC) in 2009. However, with the development of treatment for lung cancer, prognosis of lung cancer after the treatment would be significantly changed, and the 7th edition staging may be difficult to meet current clinical needs. Therefore, the International Association for the Study of Lung Cancer (IASLC) started a research to establish objectives for the T, the N, and the M components to inform the 8th edition of the TNM classification of lung cancer in 2014. Despite the large number of patients, not all descriptors could be validated. This prompted a new collection of retrospective and prospective data to overcome the limitations of the original retrospective database. The new IASLC database has information on 94 708 new patients diagnosed of lung cancer between 1999 and 2010. After analysis of the new database, IASLC formed the basis of recommendations to the UICC and AJCC for the revision of the 7th edition of TNM classification of lung cancer. They published the revised version of the 8th edition of TNM classification of lung cancer in 2015. This article would like to try to interpret this revision in details.

     

  • [1] Rami-Porta R, Bolejack V, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer[J]. J Thorac Oncol, 2015, 10(7): 90 0-1003.
    [2] Asamura H, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer[J]. J Thorac Oncol, 2015, 10(12): 1675-84.
    [3] Eberhardt WE, MitcheⅡ A, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer[J]. J Thorac Oncol, 2015, 10(11): 15 15-22.
    [4] Rami-Porta R, Bolejack V, Giroux DJ, et al. The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer[J]. J Thorac Oncol, 2014, 9(11): 1618-24.
    [5] Wittekind C, Compton C, Brierley J, et al. TNM Supplement A Commentary on Uniform Use 4th Ed[M]. Oxford: Wiley- Blackwell, 2012: 6.
    [6] Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ ATS/ERS classification of lung adenocarcinoma: prognostic subgroups andimplications for further revision of staging based on analysis of 514 stage I cases[J]. Mod Pathol, 2011, 24(5): 653-64.
    [7] Tsutani Y, Miyata Y, Nakayama H, et al. Prognostic significance ofusing solid versus whole tumor size on high-resolution computed tomography for predicting pathologic malignant grade of tumors in clinical stage IA lung adenocarcinoma: a multicenter study[J]. J Thorac Cardiovasc Surg, 2012, 143(3): 607-12.
    [8] Maeyashiki T, Suzuki K, Hattori A, et al. The size of consolidation on thin-section computed tomographyis a better predictor of survival than the maximum tumourdimension in resectable lung cancer[J]. Eur J Cardiothorac Surg, 2013, 43(5): 915-8.
    [9] Edge SB, Byrd DR, Compton CC, et al. Cancer Staging Manual 7t h Ed[M]. New York: Springer, 2010: 253-70.
    [10] Goldstraw P. Staging manual in thoracic oncology[M]. Orange Park, FL: Editorial Rx Press, 2009: 32-3.
    [11] Sobin LH, Gospodarowocz MK, Wittekind C. TNM Classification of Malignant Tumours, 7th Edition[M]. Oxford: Wiley-Blackwell, 20 09: 7-9.
    [12] Kudo Y, Saji H, Shimada Y, et al. Impact of visceral pleural invasion onthe survival of patients with non-small cell lung cancer[J]. Lung Cancer, 2012, 78(2): 153-60.
    [13] Fibla JJ, Cassivi SD, Brunelli A, et al. Re-evaluation of the prognosticvalue of visceral pleura invasion in Stage IB nonsmall cell lung cancerusing the prospective multicenter ACOSOG Z0030 trial data set[J]. Lung Cancer, 2012, 78(3): 259-62.
    [14] Kawase A, Yoshida J, Miyaoka E, et al. Visceral pleural invasion classification in non-small-cell lung cancer in the 7th edition of the tumor, node, metastasis classification for lung cancer: validation analysis based on a large-scale nationwide database[J]. J Thorac Oncol, 2013, 8(5): 606-11.
    [15] Padilla J, Calvo V, MorcilloA, et al. Resection of bronchogenic carcinoma invading the diaphragm[J]. Arch Bronconeumol, 1999, 35 (6): 297-8.
    [16] Rocco G, Rendina EA, Meroni A, et al. Prognostic factors aftersurgical treatment of lung cancer invading the diaphragm[J]. Ann Thorac Surg, 1999, 68(6): 2065-8.
    [17] Yokoi K, Tsuchiya R, Mori T, et al. Results of surgical treatmentof lung cancer involving the diaphragm[J]. J Thorac Cardiovasc Surg, 2000, 120(4): 799-805.
    [18] Galetta D, Borri A, Casiraghi M, et al. Outcome and prognostic factorsof resected non-small-cell lung cancer invading the diaphragm[J]. Interact Cardiovasc Thorac Surg, 2014, 19(4): 632-6.
    [19] Wei S, Asamura H, KawachiR, et al. Which is the better prognostic factor for resected non-small cell lung cancer: the numberof metastatic lymph nodes or the currently used nodal stage classification? [J] J Thorac Oncol, 2011, 6(2): 310-8.
    [20] Saji H, Tsuboi M, Shimada Y, et al. A proposal for combination of totalnumber and anatomical location of involved lymph nodes for nodal classificationin non-small cell lung cancer[J]. Chest, 2013, 14 3(6): 1618-25.
    [21] Ramirez RA, Wang CG, Miller LE, et al. Incomplete intrapulmonarylymph node retrieval after routine pathologic examination of resectedlung cancer[J]. J Clin Oncol, 2012, 30 (23): 2823-8.
    [22] Gray PJ, Mak RH, Yeap BY, et al. Aggressive therapy for patients withnon-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival[J]. Lung Cancer, 2014, 85(2): 239-44.
    [23] Tönnies M, Pfannschmidt J, Bauer TT, et al. Metastasectomy for synchronoussolitary non-small cell lung cancer metastases[J]. Ann Thorac Surg, 2014, 98(1): 249-56.
    [24] Congedo MT, Cesario A, Lococo F, et al. Surgery for oligometasta ticnonsmallcell lung cancer: long-term results from a single center experience[J]. J Thorac Cardiovasc Surg, 2012, 144(2): 444-52.
    [25] Bonnette P, Puyo P, Gabriel C, et al. Groupe Thorax. Surgical managementof non-small cell lung cancer with synchronous brain metastases[J]. Chest, 2001, 119(5): 1469-75.
    [26] Tanvetyanon T, Robinson LA, Schell MJ, et al. Outcomes of adrenalectomyfor isolated synchronous versus metachronous adrenal metastasesin non-small-cell lung cancer: a systematic review and pooled analysis[J]. J Clin Oncol, 2008, 26(7): 1142-7.
    [27] De Ruysscher D, Wanders R, Van Baardwijk A, et al. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phaseⅡtrial (Nct01282450)[J]. J Thorac Oncol, 2012, 7(10): 1547-55.
    [28] Saiama N. The 8th Edition of the TNM Classification for Lung Cancer: A Step in the Right Direction[J]. Oncology Times, 2015, 37 (20): 6-8.
计量
  • 文章访问数:  1731
  • HTML全文浏览量:  362
  • PDF下载量:  1944
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-12-30
  • 修回日期:  2016-02-17
  • 刊出日期:  2016-04-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭